Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, Scarcelli A, Pagnini C, Graziani MG, Di Paolo MC, Pranzo G, Luppino I, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Ferronato A, Perini B, Savarino E, Onidi FM, Binaghi L, Usai Satta P, Schiavoni E, Napolitano D, Scaldaferri F, Pugliese D, Pica R, Cocco A, Zippi M, Rodino S, Sebkova L, Rocco G, Sacchi C, Zampaletta C, Gaiani F, De Angelis G, Kayali S, Fanigliulo L, Lorenzetti R, Allegretta L, Scorza S, Cuomo A, Donnarumma L, Della Valle N, Sacco R, Forti G, Antonelli E, Bassotti G, Iannelli C, Luzza F, Aragona G, Perazzo P, Lauria A, Piergallini S, Colucci R, Bianco MA, Meucci C, Giorgetti G, Clemente V, Fiorella S, Penna A, De Medici A, Picchio M, Papa A. Mocci G, et al. Among authors: rodino s. Expert Opin Biol Ther. 2023 Mar;23(3):293-304. doi: 10.1080/14712598.2023.2185510. Epub 2023 Mar 2. Expert Opin Biol Ther. 2023. PMID: 36843568
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A, Elisei W, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Mocci G, Penna A, Rodino' S, Sebkova L, de Medici A, Pranzo G, Ricciardelli C, Grasso G, Scorza S, Zampaletta C, Picchio M. Tursi A, et al. Among authors: rodino s. Medicine (Baltimore). 2018 Aug;97(34):e11897. doi: 10.1097/MD.0000000000011897. Medicine (Baltimore). 2018. PMID: 30142791 Free PMC article.
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
Tursi A, Mocci G, Cuomo A, Allegretta L, Aragona G, Colucci R, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Piergallini S, Pranzo G, Rodino S, Scarcelli A, Zampaletta C, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Franceschi M, Gallina S, Grasso G, Larussa T, Luppino I, Faggiani R, Fanigliulo L, Pagnini C, Perazzo P, Sacco R, Sebkova L, Scorza S, Serio M, De Monti A, Picchio M, Elisei W, Maconi G. Tursi A, et al. Among authors: rodino s. Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2099-2108. doi: 10.26355/eurrev_202102_25115. Eur Rev Med Pharmacol Sci. 2021. PMID: 33660823 Free article. Clinical Trial.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Tursi A, et al. Among authors: rodino s. Expert Opin Biol Ther. 2022 Feb;22(2):313-320. doi: 10.1080/14712598.2022.2007881. Epub 2021 Dec 27. Expert Opin Biol Ther. 2022. PMID: 34904510
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W. Tursi A, et al. Among authors: rodino s. Eur J Intern Med. 2019 Aug;66:85-91. doi: 10.1016/j.ejim.2019.06.006. Epub 2019 Jun 14. Eur J Intern Med. 2019. PMID: 31208827
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Tursi A, et al. Among authors: rodino s. Ann Gastroenterol. 2019 Jul-Aug;32(4):392-399. doi: 10.20524/aog.2019.0377. Epub 2019 Apr 22. Ann Gastroenterol. 2019. PMID: 31263362 Free PMC article.
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Tursi A, et al. Among authors: rodino s. Eur J Gastroenterol Hepatol. 2021 May 1;33(5):670-679. doi: 10.1097/MEG.0000000000002087. Eur J Gastroenterol Hepatol. 2021. PMID: 33741797
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
Tursi A, Mocci G, Elisei W, Allegretta L, Colucci R, Della Valle N, De Medici A, Faggiani R, Ferronato A, Forti G, Larussa T, Lorenzetti R, Luzza F, Penna A, Pranzo G, Rodinò S, Sacco R, Sebkova L, Zampaletta C, Graziosi C, Picchio M, Bergna IMB, Maconi G. Tursi A, et al. Among authors: rodino s. J Gastrointestin Liver Dis. 2021 Dec 21;30(4):456-461. doi: 10.15403/jgld-3992. J Gastrointestin Liver Dis. 2021. PMID: 34812437 Free article.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A. Tursi A, et al. Among authors: rodino s. Inflamm Bowel Dis. 2023 Mar 1;29(3):376-383. doi: 10.1093/ibd/izac092. Inflamm Bowel Dis. 2023. PMID: 35579320
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
Tursi A, Mocci G, Cuomo A, Ferronato A, Elisei W, Picchio M, Maconi G, Scaldaferri F, Papa A; Italian group for switch of biologics; Allegretta L, Aragona G, Bianco MA, Colucci R, Della Valle N, Faggiani R, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Pica R, Pranzo G, Rodino' S, Sacco R, Sebkova L, Scarcelli A, Serio M, Napolitano D, Pugliese D, Schiavoni E, Turchini L, Armuzzi A, Zampaletta C. Tursi A, et al. Among authors: rodino s. J Gastrointestin Liver Dis. 2022 Dec 16;31(4):411-416. doi: 10.15403/jgld-4608. J Gastrointestin Liver Dis. 2022. PMID: 36535057 Free article.
47 results